Pfizer Inc. with ticker code (PFE) have now 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $50.00 and $23.00 suggesting an average Analsyt target price of $32.24. Now with the previous closing price of $29.40 this now indicates there is a potential upside of 9.7%. Also worth taking note is the 50 day moving average now sits at $29.37 and the 200 moving average now moves to $34.88. The total market capitalization for the company now stands at 164.65B. The stock price is currently at: $29.16 USD
The potential market cap would be $180,554,220,791 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 15.93, revenue per share of $12.16 and a 2.39% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
